As patent cliff levels off, biosimilars offer opportunity

09/11/2013 | Drug Store News

About $86 billion worth of branded drugs will lose patent protection between 2013 and 2017, compared with $101 billion worth of drugs that lost patent protection between 2008 and 2012, according to IMS. Biologic drugs losing patent protection may present an opportunity for other drugmakers to gain market share, but some U.S. states have passed laws restricting substitution of biosimilar drugs.

View Full Article in:

Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX